No Data
Shanxi c&y pharmaceutical group (300254.SZ) plans to establish a wholly-owned subsidiary to accelerate the research and development of new products in categories such as refined and controlled drugs.
Shanxi c&y pharmaceutical group (300254.SZ) announced that on November 25, 2024, the company's fifth board of directors will hold its twenty...
shanxi c&y pharmaceutical group (300254.SZ): Subsidiary received corporate support funds of 5 million yuan
Gelonghui, November 19th丨Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that its subsidiary Tibet Shanxi C&Y Pharmaceutical Co., Ltd. (hereinafter referred to as "Tibet Shanxi C&Y") received enterprise support funds of 5 million yuan from the Management Committee of the Tibet Autonomous Region Zangqing Industrial Park on November 19, 2024, accounting for 19.84% of the company's most recent audited net income.
shanxi c&y pharmaceutical group (300254.SZ): Currently, the company's products have not yet involved biotechnology.
Grain grains on November 11th, shanxi c&y pharmaceutical group (300254.SZ) stated on the investor interaction platform that the current company's products have not yet involved biological synthesis technology.
Qianyuan Pharmaceutical: Report for the third quarter of 2024
Shanxi C&Y Pharmaceutical Group (300254.SZ) released its performance for the first three quarters, with a net income of 44.1533 million yuan.
Shanxi C&Y Pharmaceutical Group (300254.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters was 6...
Shanxi C&Y Pharmaceutical Group (300254.SZ): net income in the third quarter was 10.6508 million yuan, a year-on-year increase of 2.11%.
Gelonghui October 23rd | Shanxi C&Y Pharmaceutical Group (300254.SZ) released the third quarter report of 2024, with revenue of 0.208 billion yuan, a year-on-year increase of 0.65%; net income attributable to shareholders of the listed company was 10.6508 million yuan, a year-on-year increase of 2.11%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 7.2156 million yuan, a year-on-year decrease of 13.35%; basic earnings per share was 0.0441 yuan.
No Data
No Data